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ABSTRACT
Background: very little is known about musculoskeletal features of multiple myeloma 
(MM) in Africa.
Objectives: To describe the musculoskeletalfeatures of multiple myeloma at presentation 
in a tertiary health care centre in sub-Saharan Africa.
Design: A Cross sectional observational study.
Setting:  The Douala General Hospital, Cameroon from 2007 to 2013. 
Subjects: A patient was said to have MM according the current international consensus 
criteria for diagnosis and staging of MM. Patients with monoclonal gammopathy of 
undetermined significance, solitary plamocytoma and other haematologic malignancies 
were excluded.
Results: A total of 62 patients were diagnosed with multiple myeloma, 63% were 
female. Mean age was 57± 12,1 (19-81) years. Musculoskeletal presentation included 
spine bone pains (75.6%); vertebral fracture with spinal cord compression in 46.8 %. 
Other clinical features at presentation included anaemia (70.93%), and nephropathy 
(17.74%). The average percentage of bone marrow plasmacytosis at diagnosis was 33% 
and Immunoglobulin G was found in 86% of patients. Sixty three per cent of patients 
were diagnosed at stage III of the disease.
Conclusion: Presence of bone pain and anaemia should alert the clinician to investigate 
along the lines of multiple myeloma. Majority of the patients have osteolytic lesions 
and pathologic fractures at the time of diagnosis.
INTRODUCTION
Multiple myeloma also known as plasma cell 
myeloma, myelomatosis, Kahler’s disease, is a 
neoplastic disorder which is characterised by 
proliferation of a single clone of plasma cells derived 
from B cells in the bone marrow, accompanied by 
production of monoclonal (M) protein. Frequently, 
thereis invasionof the adjacent bone, which destroys 
skeletal structures and results in bone pain and 
fractures. Occasionally, plasma cellsinfiltrate multiple 
organs and produce a variety of symptoms. The M 
protein can lead to renal failure (light chains called 
Bence Jones protein) or hyperviscosityfrom its 
excessive amounts in the blood. The diagnosisdepends 
on the identification of abnormal monoclonal 
plasma cells in the bone marrow, M protein in the 
serum or urine, evidence of end-organ damage and 
aclinicalpicture consistent with MM (1,2). Multiple 
myeloma represents about 2% of all cancers and 
10-12% of haematologic malignancies (3). Studies 
in Nigeria show that Multiple myeloma constitutes 
8.2% of haematologic malignancies (4). In contrast 
with the predominance of white compared to blacks 
described in most haematopoietic neoplasms, age-
adjusted incidence of MM is twofold higher in 
African Americans (9.5 per 100 000 per year) than in 
whites (4.1 per 100 000 per year); thus MM is thought 
to be more common in blacks but the race-related 
difference is not clearly understood (5) and reports 
show a consistently higher incidence and mortality 
among blacks(6-8). The principal manifestation of 
MM is musculoskeletal (bone pain and fractures), 
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followed by haematologic disturbances (anaemia), 
as a result of the accumulation of malignant plasma 
cells in the bone marrow, with frequent invasion of 
adjacent bone producing skeletal destruction(9). Few 
African studies demonstrated that bone pain and 
radiological lesions were the most important signs 
encountered, and patients were seen at late stage of the 
disease, often with complications(8, 10, 11). Fractures 
in MM are known to be associated with increased 
morbidity and poorer prognosis (12). Preventing 
this complication may help improve the outcome 
of MM in a resource poor setting (13). Even though 
Magnetic Resonance Imaging (MRI), and Computed 
Tomography/Positron Emission Tomography are 
considered gold standard diagnostic imaging tool for 
MM (3), simple plain radiographs easily accessible in 
a healthcare centre of a developing country may be 
useful in improving early diagnosis in the presence of 
MKL suggestive symptoms. In Cameroon few data is 
available on multiple myeloma: In 2005, MM though 
not found to fall among the ten most common cancers 
in Cameroon according to the Yaounde cancer registry 
(14), however accounted for 7.0% of haematologic 
malignancies diagnosed in HIV-1 patients (15) and 
3.6% of haematologic malignancies (16). Very little 
is known about musculoskeletal features of MM at 
diagnosis in our setting, as it has been stated as the 
most common presenting feature.
 The aim of this study was to describe the clinical 
features of MM, particularly the musculoskeletal 
characteristics at presentation, in view to promote 
early diagnosis and appropriate care to patients with 
MM in Cameroon.
MATERIALS AND METHODS
Research setting: The study was conducted in 
the Douala General Hospital a 320 beds referral 
tertiary health centre serving approximately four 
million inhabitants in Douala, the economic capital 
of Cameroon. This centre was chosen as it offers 
Hematology, Rheumatology and orthopedic units. All 
patients with haematologic malignancies seen in other 
units of GHD are referred to the care of oncologists 
and haematologists. MM patients were all referred 
to the haematologists.
Study design: After prior ethical clearance from 
the Institutional Review Board, we performed an 
observational cross sectional descriptive study over 
a six year-period, from January 2007 to December 
2013. Patients medical records were reviewed (One 
patient=one file) and data reported on a pre-designed, 
pre-tested data collection sheet. Clinical, laboratory, 
and radiographic profiles of these patients was 
extracted from their medical files.
Case ascertainment: Patients included for the study 
were all black Africans of Cameroonian origin 
with an established diagnosis of MM followed 
up in the Haematology unit of DGH during the 
study period. A patient was said to have MM 
accordingthe current international consensus 
criteria for diagnosis and stagingof MM (1). Patients 
with monoclonalgammopathy of undetermined 
significance, solitaryplamocytoma and other 
haematologic malignancies were excluded.
Assessment: Data collected from each patient included: 
demographic (age, sex, residence, occupation, toxic 
exposure); clinical (past and recent medical history, 
presenting complains, MKL manifestations at 
diagnosis, complications); relevant laboratory and 
radiographic findings.The normal values for Calcium, 
creatinine, Gamma globulin, beta-2- macroglobulin, 
protein immunofixation in patients were done 
according to GHD normal values. Renal impairment 
implied raised serum creatinine greater than 15mg/l. 
Anaemia was defined as haemoglobin level less than 
12 g/dl, and severe anaemia was described in patients 
with haemoglobin ≤ 8g/dl; Percentage of plasma cells 
was estimated on bone marrow aspirate: greater than 
or equal to 10% of plasma cells in the bone marrow 
aspirate of patients was considered significant. 
Measurable disease is defined as serummonoclonal 
(M) protein≥1 g/100 ml or urine M protein ≥200 mg 
per 24 h. The Durie-Salmon Staging system was used 
to grade MM: Patients were classified under stage one 
if they had one or more of the following: haemoglobin 
greater than 10g/dl, a normal skeletal survey, normal 
calcium levels and serummonoclonal (M) protein. 
Patients were classified under stage two if they had 
one or more of the following; haemoglobin between 
8 and 10g/dl, less than 3 lytic bone lesions, serum 
calcium less than 15mg/dl, and a low M protein. Those 
who were classified under stage three were expected 
to have one or more of the following; haemoglobin 
less than 8g/dl, serum calcium greater than 15mg/
dl, ≥3 lytic bone lesions and a high M protein (17).
 Radiographs features were recorded according 
to the attending radiologist description.
Statistical analysis: Categorical variables were 
presented as frequencies and continuous variables as 
mean and standard deviation. Statistical significance 
was considered at p-values < 0.05. Data were analysed 
using the Stata® software (College Station, Texas, 
USA).
RESULTS
A total of 1,206 patientswere seen in the Haematology 
unit during the study period, 470 were haematological 
malignancies, out of which 62 were diagnosed MM. 
MM thus constituted 5.1% of pathologies in the unit, 
and 13.2% of haematologic malignancies.
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Sixty-two patients fulfilled our inclusion criteria,39 
(63%) were female. The mean age was 57 ± 12.1 (19-81) 
years; 35.48% of patients were within the age group 
of 45 and 54 years. The most common presenting 
complaints were bone pain (75.6%), fatigue (64.5%) 
and inability to walk (24.2%). The complications at 
the time of diagnosis were anaemia (70.93%), spinal 
cord compression (35.5%), renal impairment (17.7%) 
and pathologic fracture (9.7%). 
 Mean values of laboratory findings included: 
haemoglobin (Hb) concentration was 9.37±2.79 (4.04 – 
16.3), total white cell count was 9.62 ± 15.01 (2.0 – 8.1) 
x103, platelets was 238.98 ± 151.14 (41 – 941), serum 
albumin was 34.09 ± 9.63 (11.27 – 60.5), and serum 
β-2 microglobulin was 15.85 ± 19.03 (0.14 – 78.20).
 The baseline demographic and clinical patients’ 
characteristics are summarised in Table 1. 
Table 1
Baseline characteristics of the population
Characteristics Items Frequency
Mean age (years)  57± 12,1 (19-81)
sex F/M 39/24





Exposure to ionising radiation n(%)   2 (3,2)
Family history of cancers n,(%)  3 (4,8)
HIV positive n,(%) 2 (3)
Presenting symptoms n,(%) Bone pain 45 (75.6)
Fatigue 40 (64.5)
Inability to walk 15 (24,9)
Complications at diagnosis n(%) Anaemia 44 (70,9)
 Spinal cord compression 22 (46,8)
 Renal impairment 11 (17,7)
 Hypercalcemia (n=51) 13 (25,5)
 Pathologic fracture 7 (14,9)
 Hyperviscosity (ESR>20mm) 40
Laboratory findings at diagnosis Mean haemoglobin 9,4 +/- 2,8 (4 - 16,3)
Mean gamma globulin 36,9 +/- 21,2(3,17- 59.6)
 Types of Immunogb(n=15)  
 Ig G 13(86.7%)
 Ig A 2(13.3%)
 Bence Jones proteinuria (n=10) 2(%)
 Medullar plasmocytosis( n=42)  
 <10 3(7.1%)
 >10 39(92.8%)
 Raised Serum β-2 microglobulin 
(n=30)
22(73.3%)
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Musculoskeletal findings at the time of diagnosis 
included bone pain: vertebral (75.6%);paraparesia 
from spinal cord compression (35.5%), diffuse bone 
pain (9.7%); hip and shoulder joint pain (6.4%). 
Radiographic lesions included: lytic lesions (57.4%), 
vertebral fracture (44.8), increased bone transparence 
considered as bone demineralisation in (44.7%). 
Table 2.
Table 2
Musculoskeletal features of MM
Characteristics Items Frequency Percentage (%)
Symptoms and signs Nerve root limb pain 1 1.61
Bone swelling 4 6.45
Joint pain 4 6.45
Rib pain 4 6.45
Diffuse bone pains 6 9.68
Vertebral bone pain 45 72.58
Spinal cord compression 22 44.8
Plain radiographs Lytic lesions 27 57.45
Vertebral fracture 22 44.80
Bone demineralisation 21 44.68
Pathologic fracture 7 14.89
No lesion found 6 12.7
Site of radiographic lesions Lumbar region 37 59.57
Long bones 14 23.40
Skull 9 14.89
On staging, 39 (62.9%) were at stage III of Durie-Salmon at the time of diagnosis. Female were more often 
involved at severe stage. Twenty-two (35.5%) patients were within 45-54 years, when diagnosed at stage III. 
Table 3 
Stage Total Gender Frequency Percentage
1 15 Female 11 17.74
 Male 4 6.45
2 8 Female 6 9.68
Male 2 3.23
3 39 Female 22 35.48
 Male 17 27.45
Total 62 62 100
DISCUSSION
Our study confirmed that bone pain is the most 
frequent clinical symptom, mainly localised in the 
spine, lytic lesion on plain radiographs and Durie 
Salmon stage III are the main presenting features of 
MM in our setting; MM is more common in female 
around their fifth decade, and patients are seen late in 
the course disease. As in retrospective data collections, 
there was lack of standardisation of tests at diagnosis 
as plain radiographs which were done mainly on 
the painful areas, may be leaving out asymptomatic 
radiographic lesions and systematic laboratory tests 
as regard to Bence Jones proteinuria, serum calcium 
level and protein immune electrophoresis were not 
systematically performed; this may render some 
results difficult to generalise in the population.
 A majority of our patients had bone pain mainly 
at the spine pain as presenting symptom. This was 
a finding similar to that in a report by other studies 
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and case reports (12,18, 19). Sudden intense back 
pain is often a sign of pathologic vertebral fracture 
that may be accompanied by neurologic symptoms, 
usually a consequence of nerve root or spinal cord 
compression. More than 50% of our study patients had 
lytic lesion and 33.87% of our study population had 
bone demineralisation on skeletal plain radiographs. 
The radiographic appearance of myelomas is variable 
depending on the clinical type; which may vary 
from myeloma induced osteoporosis, osteolyses or 
compression fracture; the most common picture is 
a one or numerous round or oval osteolytic lesion 
with a characteristic punch-out aspect found on plain 
radiographs of affected areas. This goes further to 
make plain radiographs a simple diagnostic tool to 
ease the choice of prompt and appropriate referral, and 
consequently better management. The mechanism 
of bone disease in MM is the fact that tumoral cells 
produce osteoclast-activating factors (OAFs) and 
inhibit osteoblasts activities through the action of 
local cytokines like Interleukine (IL) I beta, IL-6 and 
Tumor necrosis factor alpha. 
 With pathologic fracture, bony involvement is 
typically lytic in nature, thus destruction of bone and 
its replacement by tumour may lead to pain, spinal 
cord compression. The mechanism of spinal cord 
compression symptoms may be the development of 
an epidural mass with compression, a compression 
fracture of a vertebral body destroyed by tumoural 
cells, or, rarely, an extradural mass. Thirty five point 
five percent of our patients presented spinal cord 
compression at diagnosis, 9.7% had pathologic 
fracture. Fractures in MM are known to be associated 
with increased morbidity and poorer prognosis 
(12,19), spinal cord compression carries a heavy 
comorbidity making the prognosis even poorer.
Preventing this complication may help improve 
the outcome of MM in a resource poor setting (13).
Most of our patients were diagnosed with myeloma 
at stage three of Durie Salmon classification, with 
certainly more than three osteolytic lesions found at 
presentation. The late presentation of the patients in a 
tertiary health care unit raises the question of delayed 
referral by primary healthcare providers or lack of 
financial accessibility to specialised haematology 
care in our setting, as there is not medicare or 
health insurance to cover health expenditures. Early 
identification of clinical presentation of MM and early 
referral to adequate hospital units may reduce the 
number of patients seen at late stage of the disease.
Plasma-cell proliferation causes extensive skeletal 
destruction with osteolytic lesions, as well as anaemia, 
and hypercalcaemia. Fatigue was one of the most 
frequent symptom in our studywhich may correspond 
to anaemia, hypercalcaemia and hyperviscosity. 
Anaemia, hypercalcaemia,hyperviscosity were 
found in similar proportion than in other studies 
(10,20).Raised calcium, renalimpairment, anaemia, 
and bonelesions (CRAB) symptoms are the 
currentlyaccepted diagnostic criteria for diagnosis 
of symptomaticmyeloma(12,21). About 25% of tested 
patients in our study had hypercalcaemia at the 
time of diagnosis even though it wasn’t  systematically 
tested. Serum calcium is an independent predictor 
of quality of life in MM and hypercalcemiais a 
lifethreatening condition requiring emergency action 
(22).
 Anaemia was the second most frequent clinical 
sign in our study as frequently published (23,24,).
Bone marrow infiltration by plasma cells results 
in neutropenia, anaemia, and thrombocytopenia.
Gammopathy on serum protein electrophoresisis 
is more likely to turn out positive than Bence 
Jones proteinuria, and immunoglobulin G is the 
most frequent type of paraprotein found(10,11,24).
Therefore, in a resource poor setting investigations 
should be targeted at those parameters with a high 
frequency of positivity and greater diagnostic power 
in order to avert debilitating complications (10).
 The incidence of multiple myeloma is thought 
to increase with age, thus occuring more frequently 
in the elderly men with a mean age at diagnosis of 
69 years (22-24).The mean age of our patients was 
57 years closer to some reports (7, 8, 25) and we also 
found that 6.45% of patients in our study were age 
less than 40 and this finding as in a few studies (19, 
26, 27). Not only that MM is more common in black 
population, but at a younger age. 
CONCLUSION
Spinal bone pain, when associated to anaemia in 
young adults should be an index of suspicion to 
investigate multiple myeloma. Plain radiographs 
represent simple and affordable diagnostic tools 
in a resource poor setting. MM is diagnosed at late 
stage in our patients, due to delayed referral, and 
also because the most common symptom which is 
bone pain is frequently found in other pathologies. 
Larger prospective studies may be necessary 
to better characterise the common presenting 
musculoskeletal features, especially in a resource 
poor and predominantly black population to serve 
as a guide and necessary aid to early diagnosis. 
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